By generating stable NRF2 knockout HCT116 colon cancer cells (NRF2-Cas9) we found that NRF2 activation with sulforaphane (SFN), one of the most potent NRF2 inducer [26], on one hand reduced cisplatin (CDDP)-induced cancer cell death in NRF2-proficient cells, while did not affect it in NRF2-Cas9 cells, highlighting the key role for NRF2 in inhibiting cancer cell response to anticancer drugs. The gene discussed is NFE2L2; the disease is colonic neoplasm.